COVID-19 has shifted the paradigm of healthcare delivery, turning medical visits once widely done in-person into a virtual experience for both physicians and patients. As telemedicine was slowly gaining traction in the U.S. healthcare system, the pandemic prompted a surge in its use as providers scrambled to keep their offices and healthcare facilities open as state lockdowns ensued. Ipsos studies earlier in 2020 and recent interviews with key healthcare stakeholders indicate that telemedicine is here to stay…but the critical question becomes: In what way? Will it find a niche role in certain areas in the post-COVID landscape where it is as effective as in-person visits, or will barriers prove too significant to overcome for telemedicine to persist long term?
Stakeholders across the healthcare space, including pharmaceutical manufacturers, must now account for this evolving treatment landscape. Companies must look to:
- Develop a deeper understanding of the new patient journey
- Support telemedicine usage among providers
- Enable their products with appropriate support tools and programs to be successful in this new, telemedicine-enabled environment
Revisit our recorded webinar now, and download our detailed white paper which also features a Past Thinking + New Thinking map, together with our New Needs analysis and tips.